Physician profile
Hans Frederick Otto
NPI 1215924477
$381,234.22
in general payments reported to CMS, 2019-2025
38 companies · $107K in 2025
The $107K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $6,429 · 2021: $29K · 2022: $26K · 2023: $45K · 2024: $111K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Consulting Fee: $16K · Food and Beverage: $16K · Travel and Lodging: $7,505 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,305.00 |
| Consulting Fee | $16,216.00 |
| Food and Beverage | $16,156.55 |
| Travel and Lodging | $7,504.92 |
| Education | $171.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $297,186.70 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $23,042.94 | 2019-2025 | Dupixent |
| Amgen INC. | $19,556.13 | 2021-2025 | Tezspire, Actimmune |
| Genzyme Corporation | $15,883.26 | 2019-2025 | |
| Genentech USA, INC. | $12,005.17 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $7,032.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,771.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $442.32 | 2019-2025 | Haegarda, Kcentra, Hizentra |
| Optinose US, INC. | $379.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.21 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Pfizer INC. | $332.00 | 2019-2025 | |
| Alk-Abello, INC | $331.84 | 2019-2021 | |
| Grifols USA, LLC | $314.58 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $299.74 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $205.55 | 2019-2023 | Cinqair |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $152.83 | 2021-2022 | |
| Kaleo, INC. | $125.10 | 2019-2022 | |
| Mylan Specialty L.P. | $113.89 | 2019-2021 | |
| Hospira, INC. | $93.57 | 2024-2025 | |
| Covis Pharma Gmbh | $71.62 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $63.27 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.82 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $46.47 | 2025 | Dawnzera |
| Azurity Pharmaceuticals, INC. | $36.31 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $34.84 | 2024 | Ayvakit |
| Octapharma USA, INC. | $34.12 | 2025 | Panzyga |
| Hikma Pharmaceuticals USA | $33.48 | 2022-2024 | Ryaltris |
| Kyowa Kirin, INC. | $28.59 | 2025 | |
| Paratek Pharmaceuticals, INC. | $27.46 | 2025 | Xhance |
| Galderma Laboratories, L.P. | $20.61 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $19.83 | 2024 | Ruconest |
| Organon LLC | $19.75 | 2025 | Vtama |
| Leo Pharma INC. | $17.64 | 2023 | Adbry |
| Uswm, LLC | $17.00 | 2021 | |
| Incyte Corporation | $16.57 | 2025 | Opzelura |
| Abbvie INC. | $15.36 | 2024 | |
| Eyevance Pharmaceuticals LLC | $15.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.